Crystalline forms of an inhibitor of 11-β-hydroxysteroid dehydrogenase type 1
Novel crystalline salts of 3-[4-(3-ethanesulfonyl-propyl)-bicyclo[2.2.2]oct-1-yl]-4-methyl-5-(2-trifluoromethyl-phenyl)-4H-1,2,4-triazole are potent inhibitors of 11β-hydroxysteroid dehydrogenase Type 1 and are useful for the treatment of conditions associated with Metabolic Syndrome as well as cognitive impairment. The invention also relates to pharmaceutical compositions containing these novel salts, processes to prepare these salts and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes, hyperglycemia, obesity, dyslipidemia, hypertension, and cognitive impairment.
Merck Sharp & Dohme Corp.
A A A A C A A
A61P A61P A61P A61P C07D A61P A61P
inventional inventional inventional inventional inventional inventional inventional
Frederick T. Jungjun Joseph E. John L. Russell R. Robert M. Yuri Y. Jinchu
Mattrey Yin Lynch Leazer, Jr. Ferlita Wenslow, Jr. Bereznitski Liu